Project title | Bio-Hub -National R&D, Production, Marketing and Distribution Platform for Innovative Biopharmaceuticals
Project code | 28
Region of intervention | Lisbon
Beneficiary entity | LX Bio – Pharmarceuticals, S.A.  |  TechnoPhage- Research and Development in Biotechnology, S.A.  |  Vector B2B – Drug Developing- Association for Biotechnology Research  |  Faculty of Pharmacy, University of Lisbon
Approval date | 22-07-2022
Start date| 02-01-2023
End date | 31-12-2025
Total eligible cost | 35 167 058,56 €
Regional public financial support | LXBio – 8 212 079,17€  |  Technophage – 5 442 437,19€  |  VectorB2B – 4 581 811,11€  |  FFUL – 1 004 357,14€
Objectives, activities and expected results | The Bio-Hub consortium, led by LX Bio in partnership with the other co-promoters, aims to increase the horizon for the development of innovative biological medicines, conducting clinical trials last phases, performing the registration, marketing and distribution (export) of these drugs from Portugal, and maintaining the decision center in Portugal. This strategy will increase the exportation volume of high added value products and the promotion of highly qualified employment, allowing the development of skills in Portugal to compete, globally, in a strategic sector.